🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 890260862 (prev. 890260706 )
- Market Cap
- Micro Cap
- IPO
- 8/9/2013 · $4.25/unit
Business: Tonix Pharmaceuticals Holding Corp. is developing innovative pharmaceutical products to address public health challenges. TNX-102 SL is in Phase 3 development and has been granted Breakthrough Therapy designation by the FDA for the treatment of PTSD.
Notes: Dec. 03, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. On November 1, 2019, Tonix effected a 1-for-10 reverse stock split of its outstanding common stock intended to increase the per share trading price of Tonix’s common stock to satisfy the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Global Market, as set forth in NASDAQ Listing Rule. _______________ March 17, 2017 -- Tonix Pharmaceuticals Holding Corp. (TNXP) will effect a one-for-ten (1-10) reverse split of its common stock. The CUSIP number will change to 890260409.
Company Contact
- CEO
- Seth Lederman
- CFO
- Bradley Saenger
- Headquarters
- 26 Main Street, Suite 101, Chatham, NJ 07928
- Phone
- 862-766-8599
- Fax
- 212-923-5700
- Investor Relations
- Bradley Saenger · 212-688-9421 · investor.relations@tonixpharma.com